EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Omega-3 fatty acid supplements and risk of atrial fibrillation and ‘micro-atrial fibrillation’: A secondary analysis from the OMEMI trial

Peder L Myhre, Trygve Berge, Are A Kalstad, Sjur H Tveit, Kristian Laake, Erik B Schmidt, Svein Solheim, Harald Arnesen, Ingebjørg Seljeflot, Arnljot Tveit

Clinical Nutrition · 2023

DOI: 10.1016/j.clnu.2023.07.002 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Nutrition, 2023. Verfasst von Peder L Myhre und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Division of Medicine, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, University of Oslo, …. Hauptthemen laut MEDLINE: Fatty Acids, Omega-3, Atrial Fibrillation, Myocardial Infarction. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Recent randomized clinical trials have raised concerns regarding potential off target adverse effects from supplementation of n-3 polyunsaturated fatty acids (PUFA) on atrial fibrillation (AF) risk. We aimed to assess risk and potential mediators of AF and 'micro-AF' from n-3 PUFA in post-myocardial infarction (MI) patients. METHODS: In the OMEMI trial, 70-82 y. o. patients with a recent MI were randomized to 1.8 g/day of eicosapentaenoic-/docosahexaenoic acid (EPA/DHA) or placebo (corn oil) for two years. New-onset AF and 'micro-AF' was recorded by clinical detection and by screening with Zenicor thumb-ECG (adjudicated by blinded investigators). Serum EPA and DHA were measured at baseline and study end. RESULTS: At baseline, 759 of 1014 (75%) patients had no AF history. These patients were aged 75 ± 4 years and 71% were male. During follow-up, 43 patients developed new-onset AF (39 clinically-detected and 4 by thumb-ECG screening). In addition, 27 patients had episodes of micro-AF, yielding a total of 70 patients with new-onset AF or 'micro-AF'. In the n-3 PUFA group 46 (11.9%) had AF/'micro-AF' (28 AF, 18 'micro-AF') and in the placebo group 24 (6.5%) had AF/micro-AF (15 AF, 9 micro-AF); HR 1.90 (95%CI 1.16-3.11), P = 0.011. Changes in serum EPA (but not DHA) mediated the effect from n-3 PUFA on AF risk, explaining 65% of the association. CONCLUSION: Supplementation of n-3 PUFA post MI increases the risk of 'micro-AF' and AF, and increases in EPA seems to be an important mediator of the treatment effect from n-3 PUFA on the risk of AF. STUDY REGISTRATION: OMEMI Study; ClinicalTrails.gov identifier: NCT0184194.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fatty Acids, Omega-3Atrial FibrillationMyocardial InfarctionHumansMaleFemaleDietary SupplementsEicosapentaenoic AcidDocosahexaenoic Acids

Stichwörter der Autor:innen

Atrial fibrillationDocosahexaenoic acidEicosapentaenoic acidOmega-3 PUFA

Substanzen

Fatty Acids, Omega-3Eicosapentaenoic AcidDocosahexaenoic Acids

Autor:innen und Institutionen

  • Department of Cardiology, Division of Medicine, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, University of Oslo, Norway. Electronic address: p.l.myhre@medisin.uio.no.
  • Institute of Clinical Medicine, University of Oslo, Norway; Department of Medical Research, Vestre Viken Hospital Trust, Bærum Hospital, Gjettum, Norway.
  • Institute of Clinical Medicine, University of Oslo, Norway; Center for Clinical Heart Research, Department of Cardiology, Oslo University Hospital Ullevål, Oslo, Norway.
  • Department of Cardiology, Division of Medicine, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, University of Oslo, Norway.
  • Center for Clinical Heart Research, Department of Cardiology, Oslo University Hospital Ullevål, Oslo, Norway.
  • Aalborg University, Aalborg, Denmark.

Zitieren

APA

Myhre, P. L., Berge, T., Kalstad, A. A., Tveit, S. H., Laake, K., Schmidt, E. B., Solheim, S., Arnesen, H., Seljeflot, I., & Tveit, A. (2023). Omega-3 fatty acid supplements and risk of atrial fibrillation and ‘micro-atrial fibrillation’: A secondary analysis from the OMEMI trial. Clinical Nutrition. https://doi.org/10.1016/j.clnu.2023.07.002

Vancouver

Myhre PL, Berge T, Kalstad AA, Tveit SH, Laake K, Schmidt EB, et al. Omega-3 fatty acid supplements and risk of atrial fibrillation and ‘micro-atrial fibrillation’: A secondary analysis from the OMEMI trial. Clinical Nutrition. 2023. doi:10.1016/j.clnu.2023.07.002

BibTeX
@article{Myhre2023,
  author = {Myhre, Peder L and Berge, Trygve and Kalstad, Are A and Tveit, Sjur H and Laake, Kristian and Schmidt, Erik B and Solheim, Svein and Arnesen, Harald and Seljeflot, Ingebjørg and Tveit, Arnljot},
  title = {Omega-3 fatty acid supplements and risk of atrial fibrillation and ‘micro-atrial fibrillation’: A secondary analysis from the OMEMI trial},
  journal = {Clinical Nutrition},
  year = {2023},
  doi = {10.1016/j.clnu.2023.07.002}
}
Kostenlos starten →